810 EFFECT OF CILNIDIPINE ON SYMPATHETIC NERVOUS SYSTEM AND PLASMA ALDOSTERONE CONCENTRATION IN HYPERTENSIVE PATIENTS WITH TYPE 2 DIABETES MELLITUS

2012 ◽  
Vol 30 ◽  
pp. e235
Author(s):  
Masami Tanaka ◽  
Atsuhiro Ichihara ◽  
Hiroshi Itoh
Author(s):  
O. А. Pankova ◽  

The article analyzes the results of conducted studies about the effect of catestatin on the development of arterial hypertension and type 2 diabetes mellitus, since hyperactivation of the sympathetic nervous system is a powerful pathogenetic mechanism of their progression. This paper considers the causes of increased secretion and release of catecholamines due to the activity of the sympathetic nervous system and its impact on the reduction of catestatin levels, which has an inhibitory effect blocking nicotinic acetylcholine receptors. Non-synonymous single nucleotide polymorphisms of the catestatin domain Gly364Ser, Pro370Leu, Arg374Gln, Gly367Val and the difference of their antiadrenergic activity in comparison with the wild type of catestatin are studied, the reasons of changes in the efficiency of catestatin alleles are determined. It is estimated the pathogenetic significance of low levels of catestatin in the development of hypertension through the mechanisms of impaired vasodilation and inhibition of catecholamines. The predictive significance of catestatin is based on decrease in its level in persons with hereditary predisposition to the development of arterial hypertension. The anti-inflammatory effect of catestatin determines its role in the pathogenesis of diseases accompanied by chronic inflammation, including type 2 diabetes mellitus and atherosclerosis. The role of catestatin in the regulation of glucose metabolism due to an insulin-like effect and inhibition of glucose secretion by hepatocytes, as well as improving glucose tolerance and insulin sensitivity, has been established. The perspectives of catestatin are determined as a potential biomarker of arterial hypertension and type 2 diabetes mellitus.


Author(s):  
Yu. Urmanova ◽  
A. Holikov

THE PURPOSE OF THE STUDY is to carry out an analysis of the literature evaluating diabetic encephalopathy by determining neuromarkers. MATERIAL AND METHODS. In this article, the authors analyzed the literature on the role of neuromarkers in patients with type 2 diabetes mellitus undergoing program hemodialysis. RESEARCH RESULTS. Among biochemical markers, the determination of the level of neurospecific proteins is actively being investigated. The main part of them is autoantigens, entering the bloodstream, can cause the appearance of autoantibodies, which, when the blood-brain barrier is impaired, enter the brain from the blood vessel and cause morphological changes, destructive processes in neurons, as well as the development of nonspecific acute-phase reactions like edema or inflammation. Biomarker studies for the diagnosis of various brain lesions have been under way for more than 20 years, but at present no ideal biomarker has been found. Among biochemical markers, the determination of the level of neurospecific proteins is being actively studied. In patients with type 2 diabetes mellitus undergoing hemodialysis, this issue is also relevant in view of the frequent vascular cerebrovascular complications, but few studies have been conducted. CONCLUSIONS. All of the above emphasizes the need to identify the features of clinical and functional changes in the nervous system in patients with type 2 diabetes mellitus receiving program hemodialysis and to evaluate the prognostic value of neuromarkers in early detection of the degree of brain damage. 


Author(s):  
GA Amusa ◽  
SU Uguru ◽  
BI Awokola

Cardiovascular disease (CVD) is a common cause of morbidity/mortality in patients with type 2 diabetes mellitus (T2DM). Echocardiography can detect changes in cardiac geometry/function before overt CVD symptoms. This study aimed to evaluate left ventricular (LV) geometry and function in normotensive/hypertensive patients with T2DM without overt cardiac symptoms. A cross-sectional study in which fifty normotensives and fifty hypertensive adults with DM without overt cardiac symptoms were enrolled from the cardiology/diabetes clinics of Jos University Teaching Hospital (JUTH) in a simple random manner. Relevant history, physical examination and biochemical investigations were performed. 12-lead electrocardiography and echocardiograph assessment of LV geometry and function were also performed. Data was analyzed using Epi-info 7 statistical software; p value < 0.05 was considered significant. There were 27 females and 29 females in both groups. The prevalence of abnormal LV geometry was 36.0%, 95% CI 33.2-38.8% and 58.0%, 95% CI 55.2-60.8% in the normotensive and hypertensive groups respectively, P=0.028. Similarly, the prevalence of LV dysfunction was 38.0%, 95%CI 35.2-40.8% and 62.0%, 95%CI 59.2-64.8% respectively, P=0.017. The independent predictors of LV dysfunction were found to be duration of diabetes (OR 7.74, 95%CI 4.46-10.46), duration of hypertension ≥5years (OR 4.15, 95%CI 4.01-9.27), smoking (OR 4.34, 95%CI 1.32-6.23), body mass index ≥25 (OR 5.53, 95%CI 1.38-2.09) and glycosylated haemoglobin ≥7 (OR 7.11, 95%CI 2.15-0.81).  There is high prevalence of LV dysfunction/abnormal LV geometry in T2DM patients without overt cardiac symptoms; co-morbid hypertension worsens these abnormalities. Early and periodic echocardiography is recommended with appropriate intervention in these patients.


Sign in / Sign up

Export Citation Format

Share Document